Trademark Overview
On Friday, July 19, 2024, a trademark application was filed for ABILEAP with the United States Patent and Trademark Office. The USPTO has given the ABILEAP trademark a serial number of 98657918. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Friday, July 19, 2024. This trademark is owned by ABILITY BIOLOGICS INC. The ABILEAP trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:
antibody products and molecules acting as immune modulators for scientific and medical purposes; colostral antibodies for medical purposes; pharmaceutical antibodies for the treatment of hereditary angioedema (HAE); pharmaceutical antibodies for the treatment of respiratory diseases and respiratory syndromes; pharmaceutical antibody preparations for auto-immune diseases; pharmaceutical antibody preparations for the prevention and treatment of auto-immune diseases; pharmaceutical antibody preparations for the treatment of cancer; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories;
antibody products and molecules for scientific and medical purposes;
antibody profiling for scientific research purposes, for discovery and development of new biotherapeutics; operation of scientific database and website regarding research in the fields of cancer, immunology, inflammation, biologics, antibodies and molecules; molecule development; clinical trials; providing temporary use of a non-downloadable software for managing information in the fields of cancer, immunology, inflammation, biologics, antibodies and molecules; Platform as a service [PaaS] for analyzing molecular and clinical data to develop antibodies against immune targets; analysis in the field of molecular biology; molecular analysis and product optimization for the purpose of pharmaceutical development;
